Premium functions are now FREE OF CHARGE due to the modification of the investment data Data developments may cause some parts work incorrectly Incorrect sections - Financial statements, Earnings upcoming dates and calendars Please take our apologise. It will be fixed soon

HQL - abrdn Life Sciences Investors


Close
15.13
-0.070   -0.463%

Share volume: 52,071
Last Updated: Fri 30 Aug 2024 10:00:02 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$15.20
-0.07
-0.46%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Performance
5 Days
-0.79%
1 Month
1.88%
3 Months
18.77%
6 Months
16.34%
1 Year
30.26%
2 Year
29.23%
Key data
Stock price
$15.13
P/E Ratio 
0.00
DAY RANGE
$15.04 - $15.24
EPS 
$0.00
52 WEEK RANGE
$10.06 - $15.40
52 WEEK CHANGE
$0.30
MARKET CAP 
413.813 M
YIELD 
10.53%
SHARES OUTSTANDING 
27.351 M
DIVIDEND
$0.49
EX-DIVIDEND DATE
08/23/2024
NEXT EARNINGS DATE
N/A
BETA 
0.72
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$61,879
AVERAGE 30 VOLUME 
$65,807
Company detail
CEO:
Region: US
Website: http://www.teklacap.com/funds/hql/fund/fund-inform
Employees: 4
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry:
Sector:

tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form

Recent news